SMSbiotech

Over 70 different clinical trial teams have explored the use of Mesenchymal Stromal Cells in treating and combating COVID-19. Click below to learn more about the opportunities these cells present in treating COVID-19 and many other conditions (as well as how SMS cells interact with them).

"Cell therapy for cardiac regeneration, while promising, has been hampered by issues with long-term survival of the transplanted cells. Now, a technique that combines three different types of cells in a 3-D cluster could improve its efficacy in reducing scar tissue and improving cardiac function after a heart attack."

Dr. Abdulkader Rahmo, CEO of SMSbiotech, and Roger Schechter, M.D, sat down again to further discuss COVID-19 and it's effects on organs other than the lung, as well as some possible solutions. If you have any comments, please leave them below, and tune for more. We would love to connect with you!

In this episode, Dr. Abdulkader Rahmo, CEO of SMSbiotech, and Roger Schechter, M.D, met to discuss COVID-19: it’s effects on organs, Alveolar Type 2 cells, and so much more. Let us know what you questions you would like to ask the doctors and tune in next week for Part 2.